"Many disease areas have high incidence and great unmet medical needs in developing countries. From a company's perspective, there is a balance to be struck between developing a drug to help alleviate the disease burden in these countries and return on investment to ensure the business can survive. This session will look at the business models that have been developed to help companies develop products for these markets, such as risk-sharing with charitable organizations and multiple market strategies, as with travel vaccines."

Objective1:Explore methods of sustainably developing drugs for rare and neglected diseases.

Objective2:Encourage companies to work in these areas.

Objective3:Promote partnership between industry, institutions and the charitable sector.